Dacudao, Bebelyn P.
HRN: 21-47-20 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/24/2022
CEFUROXIME 500MG (TAB)
06/24/2022
06/30/2022
ORAL
500mg
BID
Ovarian New Growth Right; S/p Exlap Right Salpingo-oophorectomy Left Salpingectomy
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes